Table 2 Rituximab maintenance versus retreatment: comparison of efficacy
From: B cell non-Hodgkin's lymphoma: rituximab safety experience
| Â | Maintenance | Retreatment | P |
|---|---|---|---|
Overall response rate (%) | 52% | 35% | 0.14 |
Complete response rate (%) | 27% | 4% | 0.007 |
% in continuous remission | 45% | 24% | 0.05 |
% remaining in continuous remission | 23% | 2% | 0.03 |
Median progression-free survival (months) | 31.7 | 7.4 | 0.007 |
Median duration of rituximab benefit (months) | 31.7 | 27.4 | 0.94 |